person · Reporting owner

Germano Geno J

Disclosed activity across 8 companies

Tapewire entity: 16443
SEC CIK: 0001424383

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Entera Bio Ltd.ENTX · Entity 5464	Director	August 07, 2026	August 07, 2026
Harmony Biosciences Holdings, Inc.HRMY · Entity 4381	Director	May 14, 2026	May 19, 2026
PFIZER INCPFE · Entity 2863	Group President	February 25, 2015	February 27, 2015
PRECIGEN, INC.XON · Entity 4356	President	September 22, 2016	September 26, 2016
PRECISION BIOSCIENCES INCDTIL · Entity 6284	Director	September 25, 2026	September 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Entera Bio Ltd.

Report date August 07, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value NIS 0.0000769 per shareSEC Table I · non-derivative	Direct	65,014	Reported balance After 2026-08-07 transaction · row 1 1 source row Row 1 · 2026-08-07 · Grant · Acquired 25,014 · Balance 65,014 F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07	Direct	50,000	Reported balance After 2026-08-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-07 · Grant · Acquired 50,000 · Balance 50,000 F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2036-05-07	Direct	43,014	Reported balance After 2026-08-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-07 · Grant · Acquired 43,014 · Balance 43,014 F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

Filing footnotes · ownership attribution and instrument terms

F1: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

F2: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

F3: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

Harmony Biosciences Holdings, Inc.

Report date May 14, 2026 · Filed May 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.76 · Expires 2036-05-14	Direct	21,231	Reported balance After 2026-05-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-14 · Grant · Acquired 21,231 · Balance 21,231 F1: The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option shall vest in 36 equal monthly installments beginning on June 14, 2026.

PFIZER INC

Report date February 25, 2015 · Filed February 27, 2015

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	308,254	Ending reported balance After 2015-02-25 transaction · row 5 5 source rows · reconciled sequence Row 1 · 2015-02-25 · Exercise / conversion · Acquired 83,333 · Balance 354,531 F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Row 2 · 2015-02-25 · Grant · Acquired 17,893 · Balance 372,424 F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 3 · 2015-02-25 · Tax withholding · Disposed 6,474 · Balance 365,950 F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Row 4 · 2015-02-25 · Tax withholding · Disposed 24,856 · Balance 341,094 F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Row 5 · 2015-02-25 · Tax withholding · Disposed 32,840 · Balance 308,254 F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $17.69 · Expires 2015-02-25	Direct	0	Reported balance After 2015-02-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2015-02-25 · Exercise / conversion · Disposed 83,333 · Balance 0
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $34.59 · Expires 2020-02-26	Direct	144,928	Reported balance After 2015-02-26 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2015-02-26 · Grant · Acquired 144,928 · Balance 144,928 F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $34.59 · Expires 2022-02-26	Direct	120,805	Reported balance After 2015-02-26 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2015-02-26 · Grant · Acquired 120,805 · Balance 120,805 F9: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.
Common StockSEC Table I · non-derivative	IndirectBy children	1,587	Reported balance Holding disclosure · report date 2015-02-25 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,587 F7: The reporting person disclaims beneficial ownership of shares held by members of his family.
Common StockSEC Table I · non-derivative	IndirectBy Rule 16b-3 Plan	1,161	Reported balance Holding disclosure · report date 2015-02-25 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 1,161

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon).

F3: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon).

F4: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F5: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F6: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F7: The reporting person disclaims beneficial ownership of shares held by members of his family.

F8: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F9: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

PRECIGEN, INC.

Report date September 22, 2016 · Filed September 26, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to Purchase Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.94 · Expires 2026-05-31	Direct	1,000,000	Reported balance After 2016-09-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-09-22 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: This award represents the Issuer's remaining obligation to grant the reporting person option awards for 2,000,000 shares. A Form 4 dated June 3, 2016 reported that the reporting person previously received an option for 2,000,000 shares. That Form 4 has subsequently been amended to reflect that the initial grant was only effective with respect to 1,000,000 shares. This Form 4 reports that the reporting person has now received an option for the remaining 1,000,000 shares. F2: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020.

Filing footnotes · ownership attribution and instrument terms

F1: This award represents the Issuer's remaining obligation to grant the reporting person option awards for 2,000,000 shares. A Form 4 dated June 3, 2016 reported that the reporting person previously received an option for 2,000,000 shares. That Form 4 has subsequently been amended to reflect that the initial grant was only effective with respect to 1,000,000 shares. This Form 4 reports that the reporting person has now received an option for the remaining 1,000,000 shares.

F2: These options vest in 25% increments on June 1, 2017, 2018, 2019 and 2020.

PRECISION BIOSCIENCES INC

Report date September 25, 2026 · Filed September 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	47,492	Reported balance After 2026-09-25 transaction · row 1 1 source row Row 1 · 2026-09-25 · Purchase · Acquired 2,609 · Balance 47,492

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Bioverativ Inc.

Report date March 08, 2018 · Filed March 08, 2018

Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-03-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-03-08 · Disposition to issuer · Disposed 5,455 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $55.04	Direct	0	Reported balance After 2018-03-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-08 · Disposition to issuer · Disposed 21,729 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock.

F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

MEDICINES CO /DE

Report date January 06, 2020 · Filed January 06, 2020

Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-06 transaction · row 1 1 source row Row 1 · 2020-01-06 · Disposition to issuer · Disposed 7,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.90	IndirectBy grantor retained annuity trust	Reported balance After 2020-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-06 · Disposition to issuer · Disposed 27,243 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.86	IndirectBy grantor retained annuity trust	Reported balance After 2020-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-06 · Disposition to issuer · Disposed 9,141 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.81	IndirectBy grantor retained annuity trust	Reported balance After 2020-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-06 · Disposition to issuer · Disposed 8,410 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price").

F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.

F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

F4: In August 2019, the Reporting Person contributed the Options to a grantor retained annuity trust with his children as beneficiaries.

Sage Therapeutics, Inc.

Report date July 31, 2025 · Filed July 31, 2025

Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10	Direct	0	Reported balance After 2025-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time").

F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 26, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	144,928	$0.00 Strike: $34.59	$0.00	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · derivative · entry 9 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,928 Underlying: Common Stock · 144,928 shares Expires 2020-02-26 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 25, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionStock Appreciation Rights · Derivative	83,333	$0.00 Strike: $17.69	$0.00	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · derivative · entry 8 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,333 shares Expires 2015-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	32,840	$33.47	$1,099,154.80	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · nonDerivative · entry 5 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,254 F5 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F6 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document
February 25, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	24,856	$34.66	$861,508.96	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · nonDerivative · entry 4 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,094 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document
February 25, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	6,474	$34.66	$224,388.84	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · nonDerivative · entry 3 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,950 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 25, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	17,893	$0.00	$0.00	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · nonDerivative · entry 2 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,424 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 25, 2015 Filed Feb 27, 2015 23:27 UTC	PFIZER INC PFE · Entity 2863	Exercise / conversionCommon Stock	83,333	$17.69	$1,474,160.77	Disclosure SEC source: 0001225208-15-006196 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document
January 13, 2015 Filed Jan 15, 2015 19:12 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	395	$32.44	$12,813.80	Disclosure SEC source: 0001225208-15-001405 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,606 Underlying: Common Stock · 395 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
October 10, 2014 Filed Oct 14, 2014 13:36 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	446	$29.13	$12,991.98	Disclosure SEC source: 0001225208-14-021568 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,131 Underlying: Common Stock · 446 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
July 11, 2014 Filed Jul 15, 2014 17:30 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	429	$30.07	$12,900.03	Disclosure SEC source: 0001225208-14-016956 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,594 Underlying: Common Stock · 429 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
June 02, 2014 Filed Jun 4, 2014 14:17 UTC	PFIZER INC PFE · Entity 2863	SaleCommon Stock	30,000	$29.68	$890,400.00	Disclosure SEC source: 0001225208-14-014457 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,495 Read SEC document
March 31, 2014 Filed Apr 2, 2014 20:21 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	63	$32.12	$2,023.56	Disclosure SEC source: 0001225208-14-009704 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,075 Underlying: Common Stock · 63 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 14, 2014 Filed Mar 18, 2014 13:33 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	1,520	$31.23	$47,469.60	Disclosure SEC source: 0001225208-14-008426 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,012 Underlying: Common Stock · 1,520 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
February 27, 2014 Filed Feb 28, 2014 21:52 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	122,951	$0.00 Strike: $32.23	$0.00	Disclosure SEC source: 0001225208-14-006889 · doc4.xml · derivative · entry 7 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,951 Underlying: Common Stock · 122,951 shares Expires 2021-02-27 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 27, 2014 Filed Feb 28, 2014 21:52 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	154,374	$0.00 Strike: $32.23	$0.00	Disclosure SEC source: 0001225208-14-006889 · doc4.xml · derivative · entry 6 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,374 Underlying: Common Stock · 154,374 shares Expires 2019-02-27 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 27, 2014 Filed Feb 28, 2014 21:52 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	28,134	$0.00	$0.00	Disclosure SEC source: 0001225208-14-006889 · doc4.xml · nonDerivative · entry 3 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,834 F3 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document
February 26, 2014 Filed Feb 28, 2014 21:52 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	20,288	$31.99	$649,013.12	Disclosure SEC source: 0001225208-14-006889 · doc4.xml · nonDerivative · entry 2 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,700 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 26, 2014 Filed Feb 28, 2014 21:52 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	50,231	$0.00	$0.00	Disclosure SEC source: 0001225208-14-006889 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,988 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 26, 2014 Filed Mar 4, 2014 14:07 UTC Amendment	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	19,668	$31.99	$629,179.32	Disclosure SEC source: 0001225208-14-007149 · doc4a.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,320 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
December 31, 2013 Filed Jan 3, 2014 01:35 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	56	$30.63	$1,715.28	Disclosure SEC source: 0001225208-14-000195 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,431 Underlying: Common Stock · 56 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
December 13, 2013 Filed Dec 16, 2013 21:41 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	60	$30.25	$1,815.00	Disclosure SEC source: 0001225208-13-025447 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,375 Underlying: Common Stock · 60 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
November 27, 2013 Filed Dec 2, 2013 18:17 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	55	$31.88	$1,753.40	Disclosure SEC source: 0001225208-13-024406 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,315 Underlying: Common Stock · 55 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
November 15, 2013 Filed Nov 18, 2013 20:31 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	168	$32.00	$5,376.00	Disclosure SEC source: 0001225208-13-023744 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,311 Underlying: Common Stock · 168 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
October 31, 2013 Filed Nov 4, 2013 20:55 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	49	$30.69	$1,503.81	Disclosure SEC source: 0001225208-13-022780 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,143 Underlying: Common Stock · 49 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
October 15, 2013 Filed Oct 16, 2013 19:02 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	64	$29.16	$1,866.24	Disclosure SEC source: 0001225208-13-021908 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,094 Underlying: Common Stock · 64 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
September 30, 2013 Filed Oct 2, 2013 14:01 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	54	$28.73	$1,551.42	Disclosure SEC source: 0001225208-13-020977 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,030 Underlying: Common Stock · 54 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
September 13, 2013 Filed Sep 17, 2013 16:55 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	61	$28.51	$1,739.11	Disclosure SEC source: 0001225208-13-020065 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,976 Underlying: Common Stock · 61 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
August 30, 2013 Filed Sep 4, 2013 14:15 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	64	$28.21	$1,805.44	Disclosure SEC source: 0001225208-13-018980 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,915 Underlying: Common Stock · 64 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
August 15, 2013 Filed Aug 16, 2013 19:01 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	63	$28.80	$1,814.40	Disclosure SEC source: 0001225208-13-017992 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,851 Underlying: Common Stock · 63 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
July 31, 2013 Filed Aug 1, 2013 21:49 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	124	$29.23	$3,624.52	Disclosure SEC source: 0001225208-13-017087 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,788 Underlying: Common Stock · 124 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
July 15, 2013 Filed Jul 16, 2013 22:29 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	58	$28.79	$1,669.82	Disclosure SEC source: 0001225208-13-016252 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,664 Underlying: Common Stock · 58 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
June 28, 2013 Filed Jul 2, 2013 13:48 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	65	$28.01	$1,820.65	Disclosure SEC source: 0001225208-13-015230 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,606 Underlying: Common Stock · 65 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
June 26, 2013 Filed Jun 29, 2013 01:26 UTC	PFIZER INC PFE · Entity 2863	OtherCommon Stock	233	$0.00	$0.00	Disclosure SEC source: 0001225208-13-014971 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Indirect · By Rule 16b-3 Plan Disclosed balance after: 731 F1 · price: The reporting person disposed of 233 shares of Pfizer common stock in exchange for 228 shares of Zoetis Inc. Class A common stock within the Pfizer Savings and Investment Plan pursuant to a registered exchange offer to Pfizer shareholders commenced by Pfizer on May 22, 2013. The closing price of a share of Zoetis Inc. Class A common stock on the New York Stock Exchange on June 21, 2013, the trading day immediately preceding the day on which Pfizer accepted Pfizer shares that had been validly tendered and not validly withdrawn, was $30.60. Read SEC document
June 24, 2013 Filed Jun 26, 2013 19:46 UTC	PFIZER INC PFE · Entity 2863	Disposition to issuerCommon Stock	217	$0.00	$0.00	Disclosure SEC source: 0001225208-13-014872 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,726 F1 · kind: The Compensation Committee of the Board of Directors of Pfizer Inc. (Pfizer) has approved the disposition of these shares of Pfizer common stock. F2 · price: The reporting person disposed of 217 shares of Pfizer common stock in exchange for 214 shares of Zoetis Inc. Class A common stock (plus cash in lieu of a fractional share) pursuant to a registered exchange offer to Pfizer shareholders commenced by Pfizer on May 22, 2013. The closing price of a share of Zoetis Inc. Class A common stock on the New York Stock Exchange on June 21, 2013, the trading day immediately preceding the day on which Pfizer accepted Pfizer shares that had been validly tendered and not validly withdrawn, was $30.60. Read SEC document
June 14, 2013 Filed Jun 18, 2013 17:07 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	55	$29.09	$1,599.95	Disclosure SEC source: 0001225208-13-014500 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,541 Underlying: Common Stock · 55 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
May 31, 2013 Filed Jun 3, 2013 22:31 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	71	$27.23	$1,933.33	Disclosure SEC source: 0001225208-13-013702 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,486 Underlying: Common Stock · 71 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
May 15, 2013 Filed May 16, 2013 23:30 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	117	$29.56	$3,458.52	Disclosure SEC source: 0001225208-13-012565 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,415 Underlying: Common Stock · 117 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
April 30, 2013 Filed May 1, 2013 22:23 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	61	$29.07	$1,773.27	Disclosure SEC source: 0001225208-13-010916 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,298 Underlying: Common Stock · 61 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
April 15, 2013 Filed Apr 17, 2013 12:09 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	53	$30.45	$1,613.85	Disclosure SEC source: 0001225208-13-010055 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,237 Underlying: Common Stock · 53 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 28, 2013 Filed Apr 1, 2013 20:16 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	57	$28.86	$1,645.02	Disclosure SEC source: 0001225208-13-008773 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,184 Underlying: Common Stock · 57 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 15, 2013 Filed Mar 18, 2013 21:48 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	1,810	$28.02	$50,716.20	Disclosure SEC source: 0001225208-13-007873 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 Underlying: Common Stock · 1,810 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 14, 2013 Filed Mar 14, 2013 21:54 UTC	PFIZER INC PFE · Entity 2863	SaleCommon Stock	40,000	$28.00	$1,120,000.00	Disclosure SEC source: 0001225208-13-007709 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,392 Read SEC document
February 28, 2013 Filed Mar 5, 2013 00:02 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	137,112	$0.00 Strike: $27.37	$0.00	Disclosure SEC source: 0001225208-13-006460 · doc4.xml · derivative · entry 8 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,112 Underlying: Common Stock · 137,112 shares Expires 2020-02-28 F8 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F8 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 28, 2013 Filed Mar 5, 2013 00:02 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	165,198	$0.00 Strike: $27.37	$0.00	Disclosure SEC source: 0001225208-13-006460 · doc4.xml · derivative · entry 7 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,198 Underlying: Common Stock · 165,198 shares Expires 2018-02-28 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 28, 2013 Filed Mar 5, 2013 00:02 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	12	$27.37	$328.44	Disclosure SEC source: 0001225208-13-006460 · doc4.xml · derivative · entry 6 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,317 Underlying: Common Stock · 12 shares Expires not disclosed F5 · derivative.exercise_price: Each unit represents one phantom share of common stock. F6 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F6 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
February 28, 2013 Filed Mar 5, 2013 00:02 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	17,341	$27.37	$474,623.17	Disclosure SEC source: 0001225208-13-006460 · doc4.xml · nonDerivative · entry 3 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,392 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 28, 2013 Filed Mar 5, 2013 00:02 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	27,943	$0.00	$0.00	Disclosure SEC source: 0001225208-13-006460 · doc4.xml · nonDerivative · entry 2 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,733 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document
February 28, 2013 Filed Mar 5, 2013 00:02 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	35,946	$0.00	$0.00	Disclosure SEC source: 0001225208-13-006460 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,790 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
December 28, 2012 Filed Jan 2, 2013 23:06 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	73	$24.89	$1,816.97	Disclosure SEC source: 0001225208-13-000256 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,264 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
December 14, 2012 Filed Dec 17, 2012 23:32 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	62	$25.18	$1,561.16	Disclosure SEC source: 0001225208-12-025449 · doc4.xml · derivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,191 Underlying: Common Stock · 62 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.